Kashiv BioSciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kashiv BioSciences sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Kashiv BioSciences: 3 sponsored US clinical trials, 1 recruiting.
Kashiv BioSciences sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Idiopathic Urticaria, with 1 trials.
Upper-quartile sponsor footprint
Kashiv BioSciences sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
NCT06995482
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
NCT07416955
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
NCT05774639
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Kashiv BioSciences pipeline
1 recruiting of 3 indexed (33% open); 2 completed (67%).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Chronic Idiopathic Urticaria (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kashiv BioSciences: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Kashiv BioSciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Kashiv BioSciences page
3 registered trials is a research-attention snapshot, not an endorsement of Kashiv BioSciences or any single study.
- 1 of Kashiv BioSciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Idiopathic Urticaria is the condition Kashiv BioSciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Idiopathic Urticaria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kashiv BioSciences pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.